Literature DB >> 11817547

Efficacy of three corticosteroids for the treatment of heaves.

N E Robinson1, C Jackson, A Jefcoat, C Berney, D Peroni, F J Derksen.   

Abstract

This study used a cross-over design to compare the efficacy of 3 corticosteroids for the relief of airway obstruction and inflammation in 9 heaves-affected horses. The severity of airway obstruction and inflammation was quantified by measurement of lung function and by bronchoalveolar lavage fluid (BALF) cytology, respectively. Airway obstruction was induced by stabling the horses and they remained stabled during the 10 day treatment period. Lung function was measured before treatment (baseline), at Days 3, 7, and 10 of treatment, and after 30 days at pasture. BALF cytology was investigated at baseline, Day 10, and at pasture. All 9 horses received the following 4 treatments in random order: no treatment, daily oral prednisone tablets (1 mg/kg), daily i.v. dexamethasone solution (0.1 mg/kg), and i.m. dexamethasone-21-isonicotinate (0.04 mg/kg) every 3 days. When horses received no treatment, lung function did not change significantly during stabling but improved at pasture. In all horses, daily i.v. administration of dexamethasone solution improved lung function within 3 days to levels as good as or better than those measured at pasture. Dexamethasone-21-isonicotinate was rapidly effective in 8 of 9 horses. The other horse did not respond to this drug. Prednisone tablets were without effect on Days 3 and 7 of treatment, but by Day 10, 5 of 9 horses showed some improvement in lung function. Dexamethasone i.v. solution decreased the percent neutrophils in BALF at Day 10. Other treatments had no effect on BALF cytology. These results demonstrate that dexamethasone rapidly relieved airway obstruction in heaves-affected horses. Oral prednisone had inconsistent effects but may be beneficial in some horses after more than a week of treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11817547     DOI: 10.2746/042516402776181105

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  7 in total

1.  Evaluation of coagulation via thromboelastography in healthy horses administered dexamethasone.

Authors:  Jenna Woodman; Catherine R Wagg; Søren R Boysen; Renaud Leguillette; Kyle Mizen; Marie-France Roy
Journal:  Can Vet J       Date:  2015-12       Impact factor: 1.008

Review 2.  Investigating the link between particulate exposure and airway inflammation in the horse.

Authors:  K M Ivester; L L Couëtil; N J Zimmerman
Journal:  J Vet Intern Med       Date:  2014-10-01       Impact factor: 3.333

Review 3.  Pulmonary Remodeling in Equine Asthma: What Do We Know about Mediators of Inflammation in the Horse?

Authors:  Ann Kristin Barton; Heidrun Gehlen
Journal:  Mediators Inflamm       Date:  2016-12-07       Impact factor: 4.711

Review 4.  Inhalative Nanoparticulate CpG Immunotherapy in Severe Equine Asthma: An Innovative Therapeutic Concept and Potential Animal Model for Human Asthma Treatment.

Authors:  John Klier; Sebastian Fuchs; Gerhard Winter; Heidrun Gehlen
Journal:  Animals (Basel)       Date:  2022-08-16       Impact factor: 3.231

5.  Effect of Dexamethasone and Fluticasone on Airway Hyperresponsiveness in Horses With Inflammatory Airway Disease.

Authors:  R Léguillette; T Tohver; S L Bond; J A Nicol; K J McDonald
Journal:  J Vet Intern Med       Date:  2017-05-31       Impact factor: 3.333

6.  Efficacy of inhaled budesonide for the treatment of severe equine asthma.

Authors:  J P Lavoie; M Leclere; N Rodrigues; K R Lemos; C Bourzac; J Lefebvre-Lavoie; G Beauchamp; B Albrecht
Journal:  Equine Vet J       Date:  2018-09-25       Impact factor: 2.888

7.  Inhaled ciclesonide is efficacious and well tolerated in the treatment of severe equine asthma in a large prospective European clinical trial.

Authors:  Robert Scott Pirie; Hanns-Walter Mueller; Odilo Engel; Balazs Albrecht; Marcella von Salis-Soglio
Journal:  Equine Vet J       Date:  2021-01-28       Impact factor: 2.888

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.